FDA批准强生多发性骨髓瘤组合疗法作为二线治疗方案。
FDA approves J&J's multiple myeloma combo as second-line treatment
生物技术与制药领域的最新动态
FDA approves J&J's multiple myeloma combo as second-line treatment
Helus Pharma's stock slides after psychedelic drug data face questions over dosing
New FDA bonus pilot to address 'workforce challenges'
Eli Lilly's new program aims to boost employer coverage of GLP-1s
Tenaya wins support from Alnylam in cardio disease pact
Health AI dispatch from SF
China is taking on the world’s 10 most expensive medicines
Merck KGaA drops two cancer trials on assets from SpringWorks deal
Novo Nordisk details Irish expansion; EuroAPI’s challenges continue
How hospitals have shifted from experimenting with AI to justifying its cost
Yale’s Craig Crews builds model to guide biotech startups out of academia’s ‘valley of death’
FDA's top operating official Butler to retire, deputy to take over in April
Bayer continues trimming workforce; AnaptysBio's spinoff is named
BIO chief still backs FDA's Makary despite 'head-scratcher' decisions
Sanofi licenses Sino Biopharm’s transplant drug for $135M upfront
UCB boards T cell engager train in $60M upfront deal with Antengene
Blackstone to support Teva on Sanofi-partnered TL1A with $400M
Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivant
Old school healthcare is warming up to tech
Prime Medicine reverses course to seek FDA approval of shelved therapy